Diagnostic Value of Glypican-3, Arginase-1 and Hepatocyte Paraffin Antigen -1 in Differentiating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117166

Authors

Congrong Wang

Xiangyang Shao

Xuanyu Zhang

ChunMei Xie

Juanping Yu

Xiao Xu

Jian Yang

Yu Li

Weiwen Xu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the present study was to investigate the diagnostic value of glypican-3 (GPC3), arginase-1 (Arg-1), and hepatocyte paraffin antigen 1 (HepPar-1) in differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC).

Methods: The expression of GPC3, HepPar-1 and Arg-1 were measured by immunohistochemistry in 47 cases of HCC, 29 cases of ICC and their paracancerous tissues.

Results: A high expression of GPC3, Arg-1 and HepPar-1 was observed in HCC tissues (68.09%, 76.60% and 78.72%, respectively; P>0.0125) while it was lower in ICC tissues (6.90%, 6.90% and 13.79%, respectively; P>0.0125). With regard to specificity, GPC3 performed better than Arg-1 and HepPar-1 (97.37% 1.32% and 2.63%, respectively; P<0.05). The positive rate in poorly differentiated HCC for either GPC3, Arg-1 or HepPar-1 was lower than that in well- and moderately differentiated HCC. The majority of positive samples for GPC3 and Arg-1 were grade 2+ in well-, moderately- or poorly-differentiated HCC. Combined detection of GPC3, Arg-1 and HepPar-1 could increase the sensitivity up to 89.36% and the specificity to 100.00%, comparing with any single biomarker (P<0.05).

Conclusions: GPC3, Arg-1 and HepPar-1 were all useful biomarkers in differentiating HCC from ICC. The combination models could improve the diagnosis value of HCC and help differentiating HCC from ICC.

Citing Articles

Current status and new directions for hepatocellular carcinoma diagnosis.

Tu J, Wang B, Wang X, Huo K, Hu W, Zhang R Liver Res. 2025; 8(4):218-236.

PMID: 39958920 PMC: 11771281. DOI: 10.1016/j.livres.2024.12.001.

HEPPAR1 and PIWIL2 as Panel Markers for Hepatocellular Carcinoma.

Hammad G, Magdy M, Aboushousha T, Abdelraouf A, Mamdouh S Asian Pac J Cancer Prev. 2024; 25(6):2123-2131.

PMID: 38918675 PMC: 11382836. DOI: 10.31557/APJCP.2024.25.6.2123.

Case report and literature analysis: solitary HCC- recurrence in the right maxillary sinus after curative resection.

Madzikatire T, Shan Y Front Oncol. 2024; 14:1279126.

PMID: 38347833 PMC: 10859426. DOI: 10.3389/fonc.2024.1279126.

References

Weiskirchen R . Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016; 5(2):183-7. PMC: 4824750. DOI: 10.3978/j.issn.2304-3881.2016.02.04. View

Hsiao J, Tsai C, Liang T, Chiang C, Liang H, Chen I . Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment. Int J Surg. 2017; 45:35-41. DOI: 10.1016/j.ijsu.2017.07.071. View

Cui D, Wu Y, Wen D . CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018; 22(16):5200-5205. DOI: 10.26355/eurrev_201808_15717. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Han H, Qiu Y, Shi Y, Wen W, He X, Dong L . Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe. Theranostics. 2018; 8(12):3268-3274. PMC: 6010994. DOI: 10.7150/thno.24711. View

Lin D, Mayakonda A, Dinh H, Huang P, Lin L, Liu X . Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. Cancer Res. 2017; 77(9):2255-2265. PMC: 5413372. DOI: 10.1158/0008-5472.CAN-16-2822. View

Islami F, Miller K, Siegel R, Fedewa S, Ward E, Jemal A . Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017; 67(4):273-289. DOI: 10.3322/caac.21402. View

Nassar A, Cohen C, Siddiqui M . Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009; 37(9):629-35. DOI: 10.1002/dc.21075. View

Yu J, Xu X, Ma R, Qin S, Wang C, Wang X . Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. J Clin Lab Anal. 2014; 29(2):85-93. PMC: 6806998. DOI: 10.1002/jcla.21733. View

10.

Pour A, Masir N, Rose I . Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours. Malays J Pathol. 2016; 38(3):229-233. View

11.

Clark I, Shah S, Moreira R, Graham R, Wu T, Torbenson M . A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative. Hum Pathol. 2017; 69:90-95. DOI: 10.1016/j.humpath.2017.09.007. View

12.

Sin Y, Ballantyne L, Richmond C, Funk C . Transplantation of Gene-Edited Hepatocyte-like Cells Modestly Improves Survival of Arginase-1-Deficient Mice. Mol Ther Nucleic Acids. 2018; 10:122-130. PMC: 5862027. DOI: 10.1016/j.omtn.2017.11.012. View

13.

Nishida T, Kataoka H . Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(9). PMC: 6770328. DOI: 10.3390/cancers11091339. View

14.

Chen D, Li Z, Song Q, Qian L, Xie B, Zhu J . Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases. Medicine (Baltimore). 2018; 97(50):e13356. PMC: 6320094. DOI: 10.1097/MD.0000000000013356. View

15.

Yu J, Ma Q, Zhang B, Ma R, Xu X, Li M . Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci China Life Sci. 2013; 56(3):234-9. DOI: 10.1007/s11427-013-4451-y. View

16.

Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z . Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem. 2013; 61(9):639-48. PMC: 3753886. DOI: 10.1369/0022155413492771. View

17.

Chen J, Xie C, Wang C, Wan Y, Dong Z, Li M . Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. J Fluoresc. 2017; 27(4):1479-1485. DOI: 10.1007/s10895-017-2087-1. View

18.

Fu L, Mitchell K, Cai G . Clear cell hepatocellular carcinoma diagnosed by bile duct brushing cytology. Diagn Cytopathol. 2015; 44(2):147-51. DOI: 10.1002/dc.23397. View

19.

McKnight R, Nassar A, Cohen C, Siddiqui M . Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol. 2012; 120(4):223-9. DOI: 10.1002/cncy.21184. View

20.

Fujisaki S, Takashina M, Tomita R, Sakurai K, Takayama T . [Treatments of Other Cancers and Liver Metastases after Hepatectomy for Liver Cancers]. Gan To Kagaku Ryoho. 2016; 42(12):1674-6. View